Accueil
Explorer
nav.journalClub
Tendances
Plus
synapse
⌘+K
Langue
Français
Français
Serum procalcitonin: A novel tumor biomarker for diagnosis and disease monitoring in fibrolamellar hepatocellular carcinoma | Synapse
March 3, 2026
Serum procalcitonin: A novel tumor biomarker for diagnosis and disease monitoring in fibrolamellar hepatocellular carcinoma
JN
Jean-Charles Nault
CC
Claudia Campani
Inserm
TH
Théo Z. Hirsch
Inserm
See all
Key Points
Serum procalcitonin serves as a promising tumor biomarker for diagnosing fibrolamellar hepatocellular carcinoma.
Key evidence indicates that elevated serum procalcitonin levels correlate significantly with disease presence.
Observational analysis evaluating serum levels of procalcitonin in patients diagnosed with fibrolamellar hepatocellular carcinoma.
Findings underscore the potential of serum procalcitonin in monitoring disease progression and treatment response.
Mark Helpful
Like
Save
Bookmark
Relay
Share
Mark Helpful
Like
Save
Bookmark
Relay
Share
Cite This Study
Copy
Nault et al. (Sun,) studied this question.
synapsesocial.com/papers/69a766e3badf0bb9e87decfd
https://doi.org/https://doi.org/10.1016/j.jhep.2026.01.015